The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

Leukemia Research

Volumn 28, Issue 8, 2004, Pages 785-790

  Van Den Bosch, Joan ^a   Lübbert, Michael ^b   Verhoef, Gregor ^c   Wijermans, P W ^a  

^a LEYENBURG HOSPITAL   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 Aza 2 deoxycytidine; Megakaryopoiesis; Myelodysplastic syndromes; Platelet count

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; THROMBOPOIETIN;

ADULT; ARTICLE; CELL LINEAGE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; MALE; MEGAKARYOCYTES; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; RISK FACTORS; SURVIVAL RATE; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 2942594292     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.016     Document Type: Article

References (23)

1. Steensma D.P., Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk. Res. 27(2):2003;95-120
2. Negrin R.S., Haeuber D.H., Nagler A., Olds L., Donlon T., Souza L.M., et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann. Intern. Med. 110:1989;976-984
3. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 92(1):1998;68-75
4. Greenberg P., Cox C., LeBeau M., Fenaux P., Morel P., Sanz G., et al. International scoring systems for evaluating prognosis in myelodysplastic syndromes. Blood. 89(6):1997;2079-2088
5. Webb J.J., Anderson K.C. Risks, costs and alternatives to platelet transfusion. Leuk. Lymphoma. 34:1999;71-84
6. Richel D.J., Colly L.P., Kluin-Nelemans J.C., Willemze R. The antileukemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br. J. Cancer. 64:1991;144-148
7. Wijermans P.W., Krulder J.W.M., Huygens P.C., Neve P. Continous infusion of low dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndromes. Leukemia. 11:1997;1-5
8. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low dose 5-aza-2-deoxycytidine, a DNA-hypomethylating agent for the treatment of high-risk myelodysplastic syndromes: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18:2000;956-962
9. Lübbert M., Wijermans P., Kunzmann R., Verhoef G., Bosly A., Ravoet C., et al. Cytogenetic responses in high-risk myelodysplastic syndromes following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114:2001;349-357
10. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardise response criteria for myelodysplastic syndromes. Blood. 96:2000;3671-3674
11. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomised controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J. Clin. Oncol. 20:2002;2429-2440
12. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-cancer Drugs. 8:1997;358-368
13. Koshy M., Dorn L., Bressler L., Molokie R., Lavelle D., Talischy N., et al. 5-Aza-2′-deoxycytidine and foetal haemoglobin induction in sickle cell anaemia. Blood. 96:2000;2379-2384
14. Adams J.A., Liu Yin J.A., Brereton M.L., Briggs M., Burges R., Hyde C. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryocytes in normal subjects and patients with myelodysplasia and acute myeloid leukaemia. Br. J. Haematol. 99:1997;139-146
15. Faulhaber M., Wormann B., Ganser A., Verbeek W. In vitro response of myelodysplastic megakaryocytes to megakaryocyte growth and development factor (MGDF). Ann. Hematol. 81:2002;695-700
16. Wang W., Matsuo T., Yoshida S., Mori H., Miyazaki Y., Kuriyama K., et al. Colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. Leukemia. 14:2000;1751-1756
17. Ogata K., Tamura H. Thrombopoietin and myelodysplastic syndrome. Int. J. Hematol. 72:2000;173-177
18. Hellstrom Lindberg E., Kanter-Lewensohn L., Nichol J., Ost A. Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology, Scandinavian MDS group Sweden and Norway. Br. J. Haematol. 105:1999;966-973
19. Zwierzina H., Rollinger Holzinger I., Nuessler V., Herold M., Meng Y.G. Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes. Leukemia. 12:1998;59-64
20. Hoffmann W.K., Kalina U., Kosschmieder S., Seipelt G., Hoelzer D., Ottmann O.G. Defective megakaryocytic development in myelodysplastic syndrome. Leuk. Lymphoma. 38:2000;13-19
21. Daskalakis M., Nguygen T.T., Nguen C., Guldberg P., Kohler G., Wijermans P.W., et al. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (Decitabine) treatment. Blood. 100:2002;2957-2964
22. Teofili L., Martini M., Di Mario A., Rutella S., Urbano R., Luongo M., et al. Expression of p15 (ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoiesic progenitors. Blood. 98:2001;495-497
23. Kalina U., Hofman W.K., Koschmieder S., Wagner S., Kauschat D., Hoelzer D., et al. Alteration of c-mpl-mediated signal transduction in CD 34 (positive) cells from patients with myelodysplastic syndromes. Exp. Hematol. 28:2000;1158-1163